Evogene Ltd (NAS:EVGN)
$ 0.6251 -0.008 (-1.26%) Market Cap: 31.43 Mil Enterprise Value: 16.56 Mil PE Ratio: 0 PB Ratio: 3.68 GF Score: 54/100

Q3 2022 Evogene Ltd Earnings Call Transcript

Nov 17, 2022 / 02:00PM GMT
Release Date Price: $0.74 (+0.98%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to Evogene's Third Quarter 2020 Results Conference Call. (Operator Instructions) That said, I would now like to turn over the call to Ofer Haviv Evogene's CEO. Ofer, please go ahead.

Ofer Haviv
Evogene Ltd. - CEO & President

Thank you for joining our conference call discussing and providing an update on our activities in the third quarter of 2022. WeĆ¢re focusing today's review will be on 2 topics. The first one, EvogeneĆ¢s current financial status and our plans is to strengthen it and the second one, update on directed-achievements of our subsidiaries. Following my review, Yaron Eldad, our CFO, will provide the financial summary.

After that, we will open the Q&A session. As you all know, financial markets are currently very volatile and company evaluation, especially in the Balfour Sartor, have fallen very significantly over the past 1.5 years or so. I want to highlight that Evogene has and will continue to successfully navigate those difficult times despite the many challenges. Beyond

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot